Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach

Add time:07/11/2019    Source:sciencedirect.com

The present work is an extension of our ongoing efforts towards the development and identification of new molecules with anti-HIV activity which have previously led to the discovery of arylazolylthioacetanilides as highly active NNRTIs. In this article, a series of 2-2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamide derivatives were synthesized and evaluated for in vitro anti-HIV activity. Most of the tested compounds exhibited moderate activities against wild-type HIV-1. Among them, compound 6k showed significant activity against wild-type HIV-1 with an EC50 value of 1.7 μM, along with moderate activity against wild-type reverse transcriptase (RT). The preliminary structure–activity relationship (SAR) and docking calculations of this new series of compounds were also investigated, which may help designing more potent molecules.

We also recommend Trading Suppliers and Manufacturers of methyl 2-[({[5-(3-chlorophenyl)-4-ethyl-4H-1,2,4-triazol-3-yl]sulfanyl}acetyl)amino]benzoate (cas 663212-48-4). Pls Click Website Link as below: cas 663212-48-4 suppliers

Prev:Regioselective alkylation reaction of the 2′-deoxyctidine with 9-aminomethyl derivatives of SN38
Next:High resolution 19F{1H} nuclear magnetic resonance spectroscopy and liquid chromatography–solid phase extraction–offline 1H nuclear magnetic resonance spectroscopy for conclusive detection and identification of cyanide in water samples)